TY - JOUR
T1 - Metabolic Modulation of Immunity
T2 - A New Concept in Cancer Immunotherapy
AU - Guerra, Luana
AU - Bonetti, Lynn
AU - Brenner, Dirk
N1 - Funding Information:
We acknowledge the valuable work of all investigators that we were unable to cite due to space limitations. D.B. is supported by the FNR-ATTRACT program ( A14/BM/7632103 ) and the FNR-CORE ( C18/BM/12691266 ). D.B., L.B., and L.G. are funded by the FNR-PRIDE ( PRIDE/11012546/NEXTIMMUNE ) scheme.
Publisher Copyright:
© 2020 The Authors
PY - 2020/7/7
Y1 - 2020/7/7
N2 - Immunotherapy shifted the paradigm of cancer treatment. The clinical approval of immune checkpoint blockade and adoptive cell transfer led to considerable success in several tumor types. However, for a significant number of patients, these therapies have proven ineffective. Growing evidence shows that the metabolic requirements of immune cells in the tumor microenvironment (TME) greatly influence the success of immunotherapy. It is well established that the TME influences energy consumption and metabolic reprogramming of immune cells, often inducing them to become tolerogenic and inefficient in cancer cell eradication. Increasing nutrient availability using pharmacological modulators of metabolism or antibodies targeting specific immune receptors are strategies that support energetic rewiring of immune cells and boost their anti-tumor capacity. In this review, we describe the metabolic features of the diverse immune cell types in the context of the TME and discuss how these immunomodulatory strategies could synergize with immunotherapy to circumvent its current limitations.
AB - Immunotherapy shifted the paradigm of cancer treatment. The clinical approval of immune checkpoint blockade and adoptive cell transfer led to considerable success in several tumor types. However, for a significant number of patients, these therapies have proven ineffective. Growing evidence shows that the metabolic requirements of immune cells in the tumor microenvironment (TME) greatly influence the success of immunotherapy. It is well established that the TME influences energy consumption and metabolic reprogramming of immune cells, often inducing them to become tolerogenic and inefficient in cancer cell eradication. Increasing nutrient availability using pharmacological modulators of metabolism or antibodies targeting specific immune receptors are strategies that support energetic rewiring of immune cells and boost their anti-tumor capacity. In this review, we describe the metabolic features of the diverse immune cell types in the context of the TME and discuss how these immunomodulatory strategies could synergize with immunotherapy to circumvent its current limitations.
UR - http://www.scopus.com/inward/record.url?scp=85087396293&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/32640218
U2 - 10.1016/j.celrep.2020.107848
DO - 10.1016/j.celrep.2020.107848
M3 - Review article
C2 - 32640218
AN - SCOPUS:85087396293
SN - 2211-1247
VL - 32
JO - Cell Reports
JF - Cell Reports
IS - 1
M1 - 107848
ER -